Affitech A/S, a biopharmaceutical
company listed on NASDAQ OMX
Copenhagen, is dedicated to the
discovery and development of
human antibody based therapeu-
tics in cancer and other diseases
with unmet medical needs.
History of Formation
Affitech AS was established in 1997 by a group of Norwegian and German scientists on the basis of the acquisition of the worldwide exclusive rights from German Cancer Center, Heidelberg, Germany of “Breitling “ IP which covered phagemid display of human antibodies.
In May 2009, Affitech AS was combined with Pharmexa A/S to form Affitech A/S resulting in the company now being listed on NASDAQ OMX Copenhagen.
News
NOTICE OF ANNUAL GENERAL MEETING - for documents see investor relation page and shareholder portal
To the shareholders...